Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 274

1.

Excellent translational research in oncology: A journey towards novel and more effective anti-cancer therapies.

Rajan A, Berns A, Ringborg U, Celis J, Ponder B, Caldas C, Livingston D, Bristow RG, Hecht TT, Tursz T, van Luenen H, Bono P, Helander T, Seamon K, Smyth JF, Louvard D, Eggermont A, van Harten WH.

Mol Oncol. 2016 May;10(5):645-51. doi: 10.1016/j.molonc.2015.12.007. Epub 2015 Dec 23. Review.

2.

Personalized treatments of cancer patients: a reality in daily practice, a costly dream or a shared vision of the future from the oncology community?

Arnedos M, Soria JC, Andre F, Tursz T.

Cancer Treat Rev. 2014 Dec;40(10):1192-8. doi: 10.1016/j.ctrv.2014.07.002. Epub 2014 Jul 17. Review.

PMID:
25441102
3.

COURAGE, CONVICTION ET PERSÉVÉRANCE.

Perez M, Masse R, Tursz T, Dubois G.

Bull Acad Natl Med. 2014 Dec;198(9):1621-8. French. No abstract available.

PMID:
27356363
4.

Hurdles on the road to personalized medicine.

Tursz T, Bernards R.

Mol Oncol. 2015 May;9(5):935-9. doi: 10.1016/j.molonc.2014.08.009. Epub 2014 Aug 30. Review.

5.

Pioneering quality assessment in European cancer centers: a data analysis of the organization for European cancer institutes accreditation and designation program.

Saghatchian M, Thonon F, Boomsma F, Hummel H, Koot B, Harrison C, Rajan A, de Valeriola D, Otter R, Laranja Pontes J, Lombardo C, McGrath E, Ringborg U, Tursz T, van Harten W.

J Oncol Pract. 2014 Sep;10(5):e342-9. doi: 10.1200/JOP.2013.001331. Epub 2014 Aug 12.

PMID:
25118210
6.

A gene signature for late distant metastasis in breast cancer identifies a potential mechanism of late recurrences.

Mittempergher L, Saghatchian M, Wolf DM, Michiels S, Canisius S, Dessen P, Delaloge S, Lazar V, Benz SC, Tursz T, Bernards R, van't Veer LJ.

Mol Oncol. 2013 Oct;7(5):987-99. doi: 10.1016/j.molonc.2013.07.006. Epub 2013 Jul 17.

7.

Additional prognostic value of the 70-gene signature (MammaPrint(®)) among breast cancer patients with 4-9 positive lymph nodes.

Saghatchian M, Mook S, Pruneri G, Viale G, Glas AM, Guerin S, Cardoso F, Piccart M, Tursz T, Delaloge S, van't Veer L.

Breast. 2013 Oct;22(5):682-90. doi: 10.1016/j.breast.2012.12.002. Epub 2013 Jan 21.

PMID:
23347730
8.

Implications of personalized medicine--perspective from a cancer center.

Tursz T, Andre F, Lazar V, Lacroix L, Soria JC.

Nat Rev Clin Oncol. 2011 Mar;8(3):177-83. doi: 10.1038/nrclinonc.2010.222. Review.

PMID:
21364691
9.

WIN Consortium--challenges and advances.

Mendelsohn J, Tursz T, Schilsky RL, Lazar V.

Nat Rev Clin Oncol. 2011 Mar;8(3):133-4. doi: 10.1038/nrclinonc.2010.230. No abstract available.

PMID:
21364685
10.

Intensive induction chemotherapy without methotrexate in adult patients with localized osteosarcoma: results of the Institut Gustave-Roussy phase II trial.

Assi H, Missenard G, Terrier P, Le Pechoux C, Bonvalot S, Vanel D, Meric JB, Tursz T, Lecesne A.

Curr Oncol. 2010 Nov;17(6):23-31.

11.

Updated technology to produce highly immunogenic dendritic cell-derived exosomes of clinical grade: a critical role of interferon-γ.

Viaud S, Ploix S, Lapierre V, Théry C, Commere PH, Tramalloni D, Gorrichon K, Virault-Rocroy P, Tursz T, Lantz O, Zitvogel L, Chaput N.

J Immunother. 2011 Jan;34(1):65-75. doi: 10.1097/CJI.0b013e3181fe535b.

PMID:
21150714
12.

[Communication around the cancer diagnosis: patient satisfaction and process quality in French Comprehensive Cancer Centers].

Grenier C, De Jésus A, Farsi F, Marx G, Brédart A, Peixoto O, Gameroff S, Tursz T.

Bull Cancer. 2010 Oct;97(10):1163-72. doi: 10.1684/bdc.2010.1196. French.

13.

Dendritic cell-derived exosomes for cancer immunotherapy: what's next?

Viaud S, Théry C, Ploix S, Tursz T, Lapierre V, Lantz O, Zitvogel L, Chaput N.

Cancer Res. 2010 Feb 15;70(4):1281-5. doi: 10.1158/0008-5472.CAN-09-3276. Epub 2010 Feb 9. Review.

14.

Imatinib mesylate (Gleevec): targeted therapy against cancer with immune properties.

Zoubir M, Tursz T, Ménard C, Zitvogel L, Chaput N.

Endocr Metab Immune Disord Drug Targets. 2010 Mar;10(1):1-7. Review.

PMID:
19839938
15.

Personalized immunotherapy: a siren myth?

Tesniere A, Kroemer G, Tursz T, Zitvogel L.

Per Med. 2009 Sep;6(5):469-473. doi: 10.2217/pme.09.39. No abstract available.

16.

MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: a molecular portrait of stage 4S.

Bénard J, Raguénez G, Kauffmann A, Valent A, Ripoche H, Joulin V, Job B, Danglot G, Cantais S, Robert T, Terrier-Lacombe MJ, Chassevent A, Koscielny S, Fischer M, Berthold F, Lipinski M, Tursz T, Dessen P, Lazar V, Valteau-Couanet D.

Mol Oncol. 2008 Oct;2(3):261-71. doi: 10.1016/j.molonc.2008.07.002. Epub 2008 Jul 23.

17.

Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha.

Viaud S, Terme M, Flament C, Taieb J, André F, Novault S, Escudier B, Robert C, Caillat-Zucman S, Tursz T, Zitvogel L, Chaput N.

PLoS One. 2009;4(3):e4942. doi: 10.1371/journal.pone.0004942. Epub 2009 Mar 25.

18.

Gap junction communication between autologous endothelial and tumor cells induce cross-recognition and elimination by specific CTL.

Benlalam H, Jalil A, Hasmim M, Pang B, Tamouza R, Mitterrand M, Godet Y, Lamerant N, Robert C, Avril MF, Neefjes J, Tursz T, Mami-Chouaib F, Kieda C, Chouaib S.

J Immunol. 2009 Mar 1;182(5):2654-64. doi: 10.4049/jimmunol.0800815.

19.

Need for global action for cancer control.

Boyle P, Anderson BO, Andersson LC, Ariyaratne Y, Auleley GR, Barbacid M, Bartelink H, Baselga J, Behbehani K, Belardelli F, Berns A, Bishop J, Brawley O, Burns H, Clanton M, Cox B, Currow D, Dangou JM, de Valeriola D, Dinshaw K, Eggermont A, Fitzpatrick J, Forstmane M, Garaci E, Gavin AT, Kakizoe T, Kasler M, Keita N, Kerr D, Khayat D, Khleif S, Khuhaprema T, Knezevic T, Kubinova R, Mallath M, Martin-Moreno J, McCance D, McVie JG, Merriman A, Ngoma T, Nowacki M, Orgelbrand J, Park JG, Pierotti M, Ashton LP, Puska P, Escobar CV, Rajan B, Rajkumar T, Ringborg U, Robertson C, Rodger A, Roovali L, Santini LA, Sarhan M, Seffrin J, Semiglazov V, Shrestha BM, Soo KC, Stamenic V, Tamblyn C, Thomas R, Tuncer M, Tursz T, Vaitkiene R, Vallejos C, Veronesi U, Wojtyla A, Yach D, Yoo KY, Zatonski W, Zaridze D, Zeng YX, Zhao P, Zheng T.

Ann Oncol. 2008 Sep;19(9):1519-21. doi: 10.1093/annonc/mdn426. No abstract available.

PMID:
18723552
20.

Towards quality, comprehensiveness and excellence. The accreditation project of the Organisation of European Cancer Institutes (OECI).

Saghatchian M, Hummel H, Otter R, de Valeriola D, Van Harten W, Paradiso A, Koot B, Ringborg U, Tursz T; Organisation of European Cancer Institutes.

Tumori. 2008 Mar-Apr;94(2):164-71.

PMID:
18564602
21.

Improvement of European translational cancer research. Collaboration between comprehensive cancer centers.

Ringborg U, de Valeriola D, van Harten W, Bosch AL, Lombardo C, Nilsson K, Philip T, Pierotti MA, Riegman P, Saghatchian M, Storme G, Tursz T, Verellen D.

Tumori. 2008 Mar-Apr;94(2):143-6.

PMID:
18564598
22.

Managing cancer in the EU: the Organisation of European Cancer Institutes (OECI).

Ringborg U, Pierotti M, Storme G, Tursz T; European Economic Interest Grouping.

Eur J Cancer. 2008 Apr;44(6):772-3. doi: 10.1016/j.ejca.2008.01.012. Epub 2008 Mar 11.

PMID:
18337086
23.

p53 status correlates with histopathological response in patients with soft tissue sarcomas treated using isolated limb perfusion with TNF-alpha and melphalan.

Muret J, Yacoub M, Terrier P, Drusch F, Laplanche A, Gaudin C, Richon C, Le Péchoux C, Le Cesne A, Lejeune FJ, Tursz T, Fouret P, Bonvalot S, Chouaib S.

Ann Oncol. 2008 Apr;19(4):793-800. Epub 2007 Dec 6.

PMID:
18065405
24.

The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy.

Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, Mariette C, Chaput N, Mira JP, Delaloge S, André F, Tursz T, Kroemer G, Zitvogel L.

Immunol Rev. 2007 Dec;220:47-59. Review.

PMID:
17979839
25.

An unusual variant of diffuse retinoblastoma in an adult.

Khanfir K, Chompret A, Frau E, Bloch-Michel E, Tursz T, Le Cesne A.

Acta Oncol. 2008;47(5):973-4. No abstract available.

PMID:
17943473
26.

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, André F, Delaloge S, Tursz T, Kroemer G, Zitvogel L.

Nat Med. 2007 Sep;13(9):1050-9. Epub 2007 Aug 19.

PMID:
17704786
27.

Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials.

Conforti R, Boulet T, Tomasic G, Taranchon E, Arriagada R, Spielmann M, Ducourtieux M, Soria JC, Tursz T, Delaloge S, Michiels S, Andre F.

Ann Oncol. 2007 Sep;18(9):1477-83. Epub 2007 May 21.

PMID:
17515403
28.

Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells.

Ullrich E, Bonmort M, Mignot G, Chaput N, Taieb J, Ménard C, Viaud S, Tursz T, Kroemer G, Zitvogel L.

Cancer Res. 2007 Feb 1;67(3):851-3. Review.

29.

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC; IALT Bio Investigators.

N Engl J Med. 2006 Sep 7;355(10):983-91.

30.

Tobacco: deadly in any form or disguise.

Boyle P, Ariyaratne MA, Barrington R, Bartelink H, Bartsch G, Berns A, de Valeriola D, Dinshaw KA, Eggermont AM, Gray N, Kakizoe T, Karki BS, Kaslar M, Kerr DJ, Khayat D, Khuhaprema T, Kim IH, Martin-Moreno J, McVie G, Park JG, Philip T, Ringborg U, Rodger A, Seffrin JR, Semiglazov V, Soo KC, Sun YT, Thomas R, Tursz T, Veronesi U, Wiestler O, Yoo KY, Zatonski W, Zhao P.

Lancet. 2006 May 27;367(9524):1710-2. No abstract available.

PMID:
16731252
31.

Gene expression profiling of primary cutaneous melanoma and clinical outcome.

Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, Eggermont AM, Lenoir G, Sarasin A, Tursz T, van den Oord JJ, Spatz A; Melanoma Group of the European Organization for Research and Treatment of Cancer.

J Natl Cancer Inst. 2006 Apr 5;98(7):472-82.

PMID:
16595783
32.

A novel dendritic cell subset involved in tumor immunosurveillance.

Taieb J, Chaput N, Ménard C, Apetoh L, Ullrich E, Bonmort M, Péquignot M, Casares N, Terme M, Flament C, Opolon P, Lecluse Y, Métivier D, Tomasello E, Vivier E, Ghiringhelli F, Martin F, Klatzmann D, Poynard T, Tursz T, Raposo G, Yagita H, Ryffel B, Kroemer G, Zitvogel L.

Nat Med. 2006 Feb;12(2):214-9. Epub 2006 Jan 29.

PMID:
16444265
33.

Dermal lymphatic emboli in inflammatory and noninflammatory breast cancer: a French-Tunisian joint study in 337 patients.

Lê MG, Arriagada R, Contesso G, Cammoun M, Pfeiffer F, Tabbane F, Bahi J, Dilaj M, Spielmann M, Travagli JP, Tursz T, Mourali N.

Clin Breast Cancer. 2005 Dec;6(5):439-45.

PMID:
16381628
34.

In vivo veritas.

Zitvogel L, Tursz T.

Nat Biotechnol. 2005 Nov;23(11):1372-4. No abstract available.

PMID:
16273065
35.

CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.

Ghiringhelli F, Ménard C, Terme M, Flament C, Taieb J, Chaput N, Puig PE, Novault S, Escudier B, Vivier E, Lecesne A, Robert C, Blay JY, Bernard J, Caillat-Zucman S, Freitas A, Tursz T, Wagner-Ballon O, Capron C, Vainchencker W, Martin F, Zitvogel L.

J Exp Med. 2005 Oct 17;202(8):1075-85.

36.

Results of two randomized trials evaluating adjuvant anthracycline-based chemotherapy in 1146 patients with early breast cancer.

Arriagada R, Spielmann M, Koscielny S, Le Chevalier T, Delozier T, Rémé-Saumon M, Ducourtieux M, Tursz T, Hill C.

Acta Oncol. 2005;44(5):458-66.

PMID:
16118079
37.

Curbing tobacco's toll starts with the professionals: World No Tobacco Day.

Boyle P, Ariyaratne M, Bartelink H, Baselga J, Berns A, Brawley OW, Burns H, Davidov M, Dinshaw KA, Dresler C, Eggermont AM, Gajurel D, Gordina G, Gray N, Kakizoe T, Karki BS, Kásler M, Kerr DJ, Khayat D, Kiselev A, Khuhaprema T, Klocker H, Levshin V, Martin-Moreno JM, McVie JG, Mendelsohn J, Napalkov NP, Ngoma TA, Park JG, Philip T, Pötschke-Langer M, Poudal HN, Rajan B, Ringborg U, Rodger A, Seffrin JR, Shanta V, Shrestha MM, Thomas R, Tursz T, de Valeriola D, Veronesi U, Wiestler OD, Zaridze D, Zatonski W, Zeng YX.

Lancet. 2005 Jun 11-17;365(9476):1990-2. No abstract available.

PMID:
15950704
38.

Catalytic subunit of human telomerase reverse transcriptase is an independent predictor of survival in patients undergoing curative resection of hepatic colorectal metastases: a multicenter analysis.

Dômont J, Pawlik TM, Boige V, Rose M, Weber JC, Hoff PM, Brown TD, Zorzi D, Morat L, Pignon JP, Rashid A, Jaeck D, Sabatier L, Elias D, Tursz T, Soria JC, Vauthey JN.

J Clin Oncol. 2005 May 1;23(13):3086-93.

PMID:
15860868
39.

Full kringles of plasminogen (aa 1-566) mediate complete regression of human MDA-MB-231 breast tumor xenografted in nude mice.

Galaup A, Magnon C, Rouffiac V, Opolon P, Opolon D, Lassau N, Tursz T, Perricaudet M, Griscelli F.

Gene Ther. 2005 May;12(10):831-42.

PMID:
15789064
40.

Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial.

Escudier B, Dorval T, Chaput N, André F, Caby MP, Novault S, Flament C, Leboulaire C, Borg C, Amigorena S, Boccaccio C, Bonnerot C, Dhellin O, Movassagh M, Piperno S, Robert C, Serra V, Valente N, Le Pecq JB, Spatz A, Lantz O, Tursz T, Angevin E, Zitvogel L.

J Transl Med. 2005 Mar 2;3(1):10.

41.

Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy.

Arriagada R, Lê MG, Spielmann M, Mauriac L, Bonneterre J, Namer M, Delozier T, Hill C, Tursz T.

Ann Oncol. 2005 Mar;16(3):389-96. Epub 2005 Jan 27.

PMID:
15677625
42.

Exosomes for cancer immunotherapy.

Andre F, Escudier B, Angevin E, Tursz T, Zitvogel L.

Ann Oncol. 2004;15 Suppl 4:iv141-4. Review. No abstract available.

PMID:
15477298
43.

Nuclear localization of apoptosis protease activating factor-1 predicts survival after tumor resection in early-stage non-small cell lung cancer.

Besse B, Candé C, Spano JP, Martin A, Khayat D, Le Chevalier T, Tursz T, Sabatier L, Soria JC, Kroemer G.

Clin Cancer Res. 2004 Sep 1;10(17):5665-9.

44.

Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects.

Borg C, Terme M, Taïeb J, Ménard C, Flament C, Robert C, Maruyama K, Wakasugi H, Angevin E, Thielemans K, Le Cesne A, Chung-Scott V, Lazar V, Tchou I, Crépineau F, Lemoine F, Bernard J, Fletcher JA, Turhan A, Blay JY, Spatz A, Emile JF, Heinrich MC, Mécheri S, Tursz T, Zitvogel L.

J Clin Invest. 2004 Aug;114(3):379-88.

45.

Cancer funding throughout the world.

McCarthy M, Poses RM, Saghatchian M, de Pouvourville G, Tursz T, Gray A.

Lancet Oncol. 2004 Jul;5(7):453-7. No abstract available.

PMID:
15231253
46.

Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection.

Chaput N, Schartz NE, André F, Taïeb J, Novault S, Bonnaventure P, Aubert N, Bernard J, Lemonnier F, Merad M, Adema G, Adams M, Ferrantini M, Carpentier AF, Escudier B, Tursz T, Angevin E, Zitvogel L.

J Immunol. 2004 Feb 15;172(4):2137-46.

47.

Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.

André F, Chaput N, Schartz NE, Flament C, Aubert N, Bernard J, Lemonnier F, Raposo G, Escudier B, Hsu DH, Tursz T, Amigorena S, Angevin E, Zitvogel L.

J Immunol. 2004 Feb 15;172(4):2126-36.

48.

PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor.

Chompret A, Kannengiesser C, Barrois M, Terrier P, Dahan P, Tursz T, Lenoir GM, Bressac-De Paillerets B.

Gastroenterology. 2004 Jan;126(1):318-21.

PMID:
14699510
49.

Throwing a wrench in the works?

Meunier F, Dubois N, Negrouk A, Rea LA, Saghatchian M, Tursz T, Sullivan R, Law K, Tiner R.

Lancet Oncol. 2003 Dec;4(12):717-9. No abstract available.

PMID:
14662426
50.

Late local recurrences in a randomised trial comparing conservative treatment with total mastectomy in early breast cancer patients.

Arriagada R, Lê MG, Guinebretière JM, Dunant A, Rochard F, Tursz T.

Ann Oncol. 2003 Nov;14(11):1617-22.

PMID:
14581268

Supplemental Content

Support Center